Lotus Eye Hospital And Institute Ltd (LOTUSEYE) AI Stock Analysis

• Market Cap: ₹2.53B
• Dividend Yield: 0.72%
• Average Volume (3M): 28.92K
• Price to Earnings (P/E): 399.4
• Beta (1Y): 1.12
• Revenue Growth: 3.41%
• EPS Growth: -69.33%
• Country: IN
• Employees: 336
• Sector: Healthcare
• Sector Strength: 52
• Industry: Medical - Care Facilities
• EPS (TTM): 0.26
• Shares Outstanding: 20,796,330
• 10 Day Avg. Volume: 59,483
• 30 Day Avg. Volume: 28,923
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹100.00
• Price Target Upside: -21.20% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 55 Neutral
• Price Target: ₹100.00 ▼(-21.20% Downside)

Lotus Eye Hospital And Institute Ltd's stock score is primarily influenced by its strong financial foundation and revenue growth, which are offset by declining profit margins and negative free cash flow. The technical analysis indicates strong momentum but warns of potential corrections due to overbought conditions. The high P/E ratio suggests overvaluation, further impacting the overall score.

Lotus Eye Hospital And Institute Ltd Business Overview & Revenue Model

Company Description

Lotus Eye Hospital and Institute Ltd (LOTUSEYE) is a specialized healthcare provider focusing on ophthalmology services in India. The company operates a network of eye care hospitals and clinics offering a range of services including cataract surgeries, refractive surgeries, retinal surgeries, corneal transplants, and treatment for glaucoma and other eye-related conditions. Committed to delivering high-quality eye care, LOTUSEYE employs advanced technology and experienced medical professionals to serve its patients effectively.

How the Company Makes Money

Lotus Eye Hospital and Institute Ltd generates revenue primarily through the provision of eye care services. The company's main revenue streams include fees for surgical procedures such as cataract and LASIK surgeries, consultation fees, diagnostic services, and the sale of optical products like lenses and frames. Additionally, LOTUSEYE may engage in partnerships with healthcare insurance providers, enhancing its revenue intake by catering to insured patients. The company also benefits from collaborations with governmental and non-governmental organizations for eye care programs, which may include funding and grants to support its operations.

Lotus Eye Hospital And Institute Ltd Financial Statement Overview

Summary

Lotus Eye Hospital And Institute Ltd demonstrates strong revenue growth and a solid financial foundation. However, decreasing profit margins and negative free cash flow in recent years highlight the need for careful cost management and strategic capital allocation to maintain financial health. The balance sheet's low leverage provides a cushion against financial risks, but the company should focus on improving profitability and cash flow generation.

Income Statement

Lotus Eye Hospital And Institute Ltd has shown steady revenue growth, moving from ₹316.67M in 2021 to ₹495.62M in 2025. The Gross Profit Margin has decreased over the years, from 50.56% in 2021 to 20.26% in 2025, indicating increased cost pressures. The Net Profit Margin has also declined, reflecting challenges in maintaining profitability despite revenue growth.

Balance Sheet

The company maintains a strong equity base with Stockholders' Equity at ₹600.00M in 2025. The Debt-to-Equity ratio is low, suggesting prudent leverage management. However, the Equity Ratio has slightly decreased, indicating a marginal increase in liabilities over time. Overall, the balance sheet remains robust, providing a stable financial foundation.

Cash Flow

Operating Cash Flow has seen fluctuations but remained positive, providing a reliable cash flow source. However, Free Cash Flow has turned negative in recent years, driven by increased capital expenditures, indicating potential liquidity concerns if not balanced with future revenue growth.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2023	Dec 2021	Dec 2020
Income Statement
Total Revenue	489.33M	495.63M	470.44M	482.10M	380.86M	316.67M
Gross Profit	173.45M	100.41M	243.17M	135.66M	192.53M	160.14M
EBITDA	55.50M	47.44M	88.37M	79.42M	68.09M	44.59M
Net Income	5.11M	7.39M	40.77M	29.14M	29.84M	15.68M
Balance Sheet
Total Assets	0.00	695.74M	631.88M	666.27M	615.97M	592.29M
Cash, Cash Equivalents and Short-Term Investments	45.45M	41.51M	83.31M	69.30M	87.93M	98.92M
Total Debt	0.00	34.30M	6.70M	11.10M	12.38M	3.99M
Total Liabilities	-601.06M	95.73M	56.09M	72.17M	69.88M	65.32M
Stockholders Equity	601.06M	600.00M	575.79M	594.09M	546.09M	526.97M
Cash Flow
Free Cash Flow	0.00	-21.25M	12.90M	403.00K	-2.73M	22.55M
Operating Cash Flow	0.00	27.02M	43.87M	56.83M	44.12M	27.30M
Investing Cash Flow	0.00	-43.50M	-21.94M	-46.33M	-39.35M	4.86M
Financing Cash Flow	0.00	-12.42M	-17.05M	-34.02M	-15.75M	-3.19M

Lotus Eye Hospital And Institute Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 126.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LOTUSEYE, the sentiment is Positive. The current price of 126.9 is above the 20-day moving average (MA) of 98.00, above the 50-day MA of 83.34, and above the 200-day MA of 72.27, indicating a bullish trend. The MACD of 13.99 indicates Negative momentum. The RSI at 72.83 is Negative, neither overbought nor oversold. The STOCH value of 70.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LOTUSEYE.

Lotus Eye Hospital And Institute Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIJAYA	68 Neutral	₹113.72B	75.70		0.18%	22.34%	20.71%
LOTUSEYE	55 Neutral	₹2.53B	399.43		0.72%	3.41%	-69.33%
Sector *	51 Neutral	$7.95B	-0.38	-43.43%	2.22%	22.30%	-1.83%
GKB	―	₹366.15M	―		―	―	―
KRSNAA	63 Neutral	₹27.27B	33.86		0.30%	13.78%	32.21%
HCG	61 Neutral	₹96.29B	260.19		―	16.85%	-29.57%
SHALBY	57 Neutral	₹23.67B	1,145.00		0.51%	13.03%	-100.65%